Influence of the NFKB1 promotor polymorphism (-94ins/delATTG) on hydrocortisone effectiveness and mortality in septic shock

Influence of the NFKB1 promotor polymorphism (-94ins/delATTG) on hydrocortisone effectiveness and mortality in septic shock - NFKB and HC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00006111

Enrollment

160

Registered

2014-04-23

Start date

2010-02-01

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A41.9 R57.2

Interventions

Group 1: patients with septic shock, who were treated with hydrocortisone due to the decision of the clinician are evaluated regarding 30 day mortality and severity of illness (SAPS II). Blood withdra

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: septic shock

Exclusion criteria

Exclusion criteria: age <18: refusal of study participation, non caucasian ethnicity

Design outcomes

Primary

Measure	Time frame
30-day mortality	—

Countries

Germany

Contacts

Public ContactSimon Schäfer

Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Essen

simon.schaefer@uni-due.de+49 201 72384436

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026